Small Molecules

09 Apr 2019 Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
08 Apr 2019 Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
08 Apr 2019 United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
06 Apr 2019 Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
05 Apr 2019 U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
05 Apr 2019 Nanobiotix announces first ever radioenhancer to receive European market approval
04 Apr 2019 EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
04 Apr 2019 VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
03 Apr 2019 Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
03 Apr 2019 Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
03 Apr 2019 Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
03 Apr 2019 Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
03 Apr 2019 Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
03 Apr 2019 Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
02 Apr 2019 Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
02 Apr 2019 Novel First-In-Class FLIP Inhibitors for the Treatment of Cancer
02 Apr 2019 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
02 Apr 2019 Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
02 Apr 2019 Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
01 Apr 2019 Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
01 Apr 2019 BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
01 Apr 2019 Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
01 Apr 2019 Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
01 Apr 2019 Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH
01 Apr 2019 Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up